Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1169317 | 0.98 | SMN1; SMN2 (0.71) | SMN1; SMN2CA1CA2TSHRHDAC8 | |
| SCHEMBL9016956 | 0.93 | LMNA (0.68) | SMN1; SMN2CA1CA2TSHRLMNA | |
| SCHEMBL380710 | 0.91 | SMN1; SMN2 (0.71) | SMN1; SMN2CA1CA2TSHRHDAC8 | |
| Hydrochloric Acid SCHEMBL15393160 | 0.91 | LMNA (0.66) | SMN1; SMN2CA1CA2TSHRLMNA | |
| SCHEMBL4933368 | 0.89 | MEN1 (0.68) | SMN1; SMN2CA1CA2TSHRLMNA | |
| Benzene SCHEMBL27900964 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2CA1CA2TSHRLMNA | |
| SCHEMBL380994 | 0.86 | CA1 (0.73) | SMN1; SMN2CA1CA2TSHRLMNA | |
| SCHEMBL6158387 | 0.85 | TSHR (0.67) | SMN1; SMN2CA1CA2TSHRLMNA | |
| SCHEMBL1928912 | 0.85 | TSHR (0.67) | SMN1; SMN2CA1CA2TSHRLMNA | |
| SCHEMBL3310683 | 0.85 | LMNA (0.64) | SMN1; SMN2CA1CA2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331864-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| CN-108137518-B | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-08-31 | — | — | CN | disclosed |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-07-21 | — | — | US | disclosed |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-07-21 | — | — | US | disclosed |
| US-20080070954-A1 | Acylurea Connected And Sulfonylurea Connected Hydroxamates | S*BIO PTE LTD. (SG) | 2008-03-20 | — | — | US | disclosed |
| US-20080070954-A1 | Acylurea Connected And Sulfonylurea Connected Hydroxamates | S*BIO PTE LTD. (SG) | 2008-03-20 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| CN-101102796-A | Benzothiazole formulations and uses thereof | ARES TRADING SA (CH) | 2008-01-09 | — | — | CN | disclosed |
| EP-1685094-A4 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S BIO PTE LTD (SG) | 2007-08-22 | — | — | EP | disclosed |
| EP-1685094-A1 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S*Bio Pte Ltd (SG) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005040101-A1 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040101-A1 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070954-A1 | Acylurea Connected And Sulfonylurea Connected Hydroxamates | HDAC1, HDAC3, HDAC4 | SMN1; SMN2 2353/4885CA1 800/4885CA2 396/4885 |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | MGLL, MBOAT4, MBOAT1 | SMN1; SMN2 3856/4885CA1 4817/4885CA2 4062/4885 |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | SMN1; SMN2 4881/4885CA1 1090/4885CA2 912/4885 |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | SMN1; SMN2 4881/4885CA1 1090/4885CA2 912/4885 |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | SMN1; SMN2 4881/4885CA1 1090/4885CA2 912/4885 |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC1, HDAC5, HDAC2 | SMN1; SMN2 752/4885CA1 2283/4885CA2 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.